Bavarian Nordic is founded in Denmark around MVA (modified vaccinia Ankara) as a non-replicating smallpox platform. Jynneos is the later commercial expression.

FDA licenses Jynneos (smallpox and mpox) on 24 Sep 2019. The 2022 mpox outbreak turns a stockpile product into an outbreak P&L.

Vimkunya (chikungunya) approved US/EU/UK in 2025. Direct competitor to Valneva IXCHIQ in travel clinics.

Serum Institute tech-transfer for LMIC chikungunya supply (Vimkunya). Volume path is SII, not branded travel ASP.

BARDA exercises $97M more freeze-dried Jynneos options (11 May 2026). Remaining 11.5M-dose order for 2027 delivery. Public-preparedness, not ACIP retail.